<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-160863</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Treatment of Bowen disease with photodynamic therapy and the advantages of sequential topical imiquimod</dc:title>
<dc:description xml:lang="en">Photodynamic therapy (PDT) has been shown to be useful and effective in the treatment of actinic keratosis, Bowen disease, and basal cell carcinoma. We present a series of 13 Bowen disease lesions treated using PDT. Complete responses were achieved in 11 (84%) of the lesions after 3 months of treatment; at 18 months, complete responses were seen in 9 (70%) of the lesions. Patients who presented a partial response or recurrence were treated with topical 5% imiquimod and achieved complete responses. The lesions that presented partial response or recurrence were the largest lesions, between 3 and 5cm in diameter. PDT in monotherapy or combined sequentially with imiquimod is an excellent and well-tolerated therapeutic option for Bowen disease. The treatment has few adverse effects and shows satisfactory results, particularly in multiple large lesions in areas of difficult surgical reconstruction or in elderly patients with a high surgical risk (AU)</dc:description>
<dc:creator>Martínez-Leborans, L</dc:creator>
<dc:creator>Ortiz-Salvador, JM</dc:creator>
<dc:creator>Pérez-Ferriols, A</dc:creator>
<dc:creator>Victoria-Martínez, AM</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La terapia fotodinámica (TFD) ha demostrado ser un tratamiento útil y eficaz en queratosis actínicas, enfermedad de Bowen (EB) y carcinoma basocelular. Presentamos una serie de 13 lesiones de EB tratados con TFD. A los 3 meses del tratamiento 11/13 (84%) lesiones presentaron respuesta completa. A los 18 meses la respuesta completa fue de 9/13 (70%) lesiones. Los pacientes que presentaron respuesta parcial o recidiva fueron tratados con imiquimod tópico al 5%, con la consiguiente respuesta completa. Las lesiones con respuesta parcial o recidiva fueron las de mayor tamaño: entre 3 y 5cm de diámetro. La TFD en monoterapia o combinada secuencialmente con imiquimod es una excelente opción terapéutica para la EB, bien tolerada, con mínimos efectos secundarios y unos resultados satisfactorios, y sobre todo indicada en lesiones de gran tamaño, múltiples, en áreas de difícil reconstrucción quirúrgica o en pacientes ancianos con riesgo quirúrgico elevado (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;108(2): e9-e14, mar. 2017. tab, ilus</dc:source>
<dc:identifier>ibc-160863</dc:identifier>
<dc:title xml:lang="es">Tratamiento de la enfermedad de Bowen con terapia fotodinámica y ventajas de la aplicación secuencial de imiquimod tópico</dc:title>
<dc:subject>^d1938^s22059</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d1938^s22057</dc:subject>
<dc:subject>^d23421^s22066</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d287</dc:subject>
<dc:subject>^d23421^s22045</dc:subject>
<dc:subject>^d30694^s22012</dc:subject>
<dc:subject>^d30694^s22057</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:type>article</dc:type>
<dc:date>201703</dc:date>
</metadata>
</record>
</ibecs-document>
